Matinas Biopharma (MTNB) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Matinas Biopharma is the larger company by market cap ($2.8 million vs $2.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MTNB | VRAX |
|---|---|---|
| Share price | $2.83 | $1.99 |
| Market cap | $2.77M | $2.68M |
| 1-day change | +2.17% | -5.69% |
| EPS (TTM) | $-17.55 | $-11.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.95 | $21.75 |
| 52-week low | $2.27 | $1.83 |
| Distance from 52-week high | -90.22% | -90.85% |
| Average volume | 408.10K | 650.11K |
| Shares outstanding | 979.52K | 1.34M |
| Employees | 2 | 26 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Matinas Biopharma
MTNB stock →Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Healthcare · Biotechnology · 2 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Healthcare · Biotechnology · 26 employees
MTNB vs VRAX FAQ
Which is bigger, Matinas Biopharma or Virax Biolabs Group?
Matinas Biopharma (MTNB) is larger, with a market capitalization of $2.77M compared with $2.68M for Virax Biolabs Group (VRAX).
Are Matinas Biopharma and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.